CNR1 and psychotic disorder: GAT211 has been shown to mimic the effects of CB1R agonists to reduce pain, symptoms of psychosis, and symptoms of Huntington's Disease (Garai et al., 2021; Laprairie et al., 2019; McElroy et al., 2021; Slivicki et al., 2018).